Back to news and publications

Strata Oncology Enrolls First Patient in Strata PATH Trial Investigating New Pan-Tumor Indications for Approved Cancer Therapies

Trial leverages company’s novel quantitative RNA and multivariate algorithms to deliver treatment selection for all therapeutic modalities

May 11, 2022

May 11, 2022

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced enrollment of the first patient in the Strata Precision Indications for Approved THerapies (Strata PATHTM) trial, a prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations. “The Strata PATH trial is a crucial step in our mission to accelerate the impact of precision medicine for patients with cancer, in both the early- and late-stage settings,” said Dan Rhodes, PhD, co-founder and Chief Executive Officer, Strata Oncology. “There is no time to spare when it comes to getting patients their best possible therapies, so we have taken the initiative to sponsor this trial to prospectively test novel biomarker-guided treatment hypotheses that we believe may result in new, highly-responsive pan-tumor molecular indications for FDA-approved therapies.”

“We are pleased to be working with Strata Oncology on the innovative Strata PATH trial,” said Priya Jain, MD, Medical Oncologist and Principal Investigator with Kettering Health, the site of the first patient enrollment. “We are committed to bringing the latest in medical technology and advanced care to the community of patients we serve, and we are proud to be able to offer our patients the chance to enroll in this cutting-edge clinical trial.”

Strata used its clinical molecular database, developed through a previous clinical study known as the Strata TrialTM, to devise the hypotheses being tested in Strata PATH. The database includes both DNA mutation profiles and quantitative RNA expression data from tens of thousands of patients coupled with detailed treatment history and outcomes data. Enrollment for multiple arms in Stata PATH is based on novel quantitative RNA and multivariate algorithms the company developed.

“Due to the rapid clinical development of multiple therapies against expression-based targets, comprehensive genomic profiling alone is often insufficient to identify a patient’s best treatment,” said Rhodes. “Strata Oncology is making cancer treatment smarter by developing quantitative RNA and multivariate algorithms that can guide the use of a range of therapeutic classes, including antibody-drug conjugates, immunotherapies and angiogenesis inhibitors.” Strata PATH will enroll patients with advanced cancer, as well as patients with early-stage cancer who have evidence of micrometastatic disease after initial treatment. The company expects that many of the patients with micrometastatic disease will be identified through the Strata SentinelTM trial, a 100,000-patient, prospective, observational, pan-solid tumor study of Strata Oncology’s highly sensitive, tumor-informed circulating tumor DNA (ctDNA)-based MRD test. 

All therapies being evaluated in Strata PATH are FDA-approved in oncology with demonstrated safety profiles in the advanced setting. Each drug will be administered according to the FDA-approved dosing regimen listed in the approved product labeling.

Media Inquiries

Rachel Ford Hutman  rachel@fordhutmanmedia.com 301.801.5540

Media Inquiries

Rachel Ford Hutman  rachel@fordhutmanmedia.com 301.801.5540

In the news

The latest from Strata Oncology

December 1, 2023

Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers at North America Conference on Lung Cancer and San Antonio Breast Cancer Symposium

November 8, 2023

Strata Oncology Recognized as “Diagnostics Innovation Of The Year” by BioTech Breakthrough Awards

September 11, 2023

Dr. Nair on the clinical utility of Immunotherapy Response Score 

September 10, 2023

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

September 7, 2023

Strata Oncology Announces New Data Supporting Utility of Immunotherapy Response Score to Guide First-Line Treatment Decisions in Non-small Cell Lung Cancer

July 10, 2023

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

July 3, 2023

Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

June 14, 2023

Dr Thomas on the Predictive Value of IRS For Pembrolizumab Benefit in Advanced Solid Tumors

June 1, 2023

Evaluation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab (pembro) Clinical Benefit in Patients (pts) with Advanced Solid Tumors

May 2, 2023

Strata Oncology Receives Honorable Mention in Fast Company’s 2023 World Changing Ideas Awards